PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
May 7, 2026PharmaceuticsOpen Access

Harnessing Pharmacokinetic Modeling to Develop a Long-Acting Subcutaneous HIV Treatment Platform for Young Children

View Full Paper
Ask AI
Bookmark
Share

Authors

DODaniel OliveiraDCDaniela CruzLLL. Levin

Discussion

Loading...

Member takes

Overview

Pharmacokinetic modeling demonstrates favorable plasma concentrations of emtricitabine in young children, indicating effective HIV treatment.

Key Points

  • To develop a biodegradable subcutaneous implant for long-acting HIV treatment in young children.
  • Evaluated pharmacokinetic profiles in New Zealand White rabbits after intravenous and subcutaneous drug delivery.
  • Antiretrovirals quantified using HPLC-MS/MS.
  • Population pharmacokinetic models fitted to intravenous pharmacokinetic data.
  • Implants achieved quantifiable plasma concentrations for over 360 days.
  • Median absorption rates were observed at differing intervals for the drugs tested.
  • Plasma concentrations achieved were within ranges anticipated for efficacy in pediatric treatment.

Cite This Study

Oliveira et al. (2026) studied this question.

synapsesocial.com/papers/69fbe3ca164b5133a91a320ahttps://doi.org/10.3390/pharmaceutics18050522
View Full Paper
Ask AI
Bookmark
Share